News | Prostate Cancer | May 09, 2018

USPSTF Updates Recommendations for Prostate Cancer Screening

Task force recommends men ages 55-69 make an individual decision about prostate cancer screening with their clinician; recommends against routine screening for men age 70 and older

USPSTF Updates Recommendations for Prostate Cancer Screening

May 9, 2018 – The U.S. Preventive Services Task Force (USPSTF) posted a final recommendation statement and evidence summaries on screening for prostate cancer. This final recommendation provides clinicians and their patients with important new information about the benefits and harms of prostate-specific antigen (PSA)-based screening.

Based on a review of the evidence, the task force recommends that men ages 55 to 69 make an individual decision about whether to get PSA-based screening for prostate cancer. Before deciding whether to be screened, men should discuss the potential benefits and harms of screening with their clinician, their specific clinical circumstances and incorporate their values in the decision. This is a C recommendation. For men age 70 and older, the potential benefits do not outweigh the harms, and these men should not be routinely screened for prostate cancer. This is a D recommendation.

This final recommendation applies to all adult men who have no signs or symptoms of prostate cancer and who have never been diagnosed with the disease. It includes men at increased risk, such as African American men and men with a family history of prostate cancer.

“Prostate cancer is one of the most common cancers to affect men and the decision whether to be screened is complex,” said task force vice chair Alex H. Krist, M.D., M.P.H. “Men should discuss the benefits and harms of screening with their doctor, so they can make the best choice for themselves based on their values and individual circumstances.”

The PSA test measures the amount of prostate-specific antigen, a type of protein, in a man’s blood. An elevated PSA level may be caused by prostate cancer, but it could also be caused by other conditions, such as an enlarged prostate or inflammation of the prostate. PSA-based screening and the prostate biopsies used to follow-up on high PSA levels cannot tell for sure which cancers are likely to be aggressive and spread, and which will grow so slowly that they will never cause any problems. As a result, most men receive surgery or radiation to treat their prostate cancer and many of these men do not benefit from the treatments. In fact, they may even be harmed by them. For this reason, the task force stresses that men who are considering screening should understand that is has both potential benefits and potential harms.

“For men who are more interested in the small potential benefit and willing to accept the potential harms, screening may be the right choice for them,” said task force vice chair Douglas K. Owens, M.D., M.S. “Men who place more value on avoiding the potential harms may choose not to be screened.”

The task force found that the net benefit of screening is small for some men. There is new evidence that screening men aged 55 to 69 can reduce the risk of metastatic cancer and reduce the chance of dying from prostate cancer. There is also new information on active surveillance — a way of monitoring prostate cancer that may allow some men with low-risk prostate cancers to delay or, in some cases avoid, treatment with radiation or surgery. Active surveillance has become a more common choice for men with lower-risk prostate cancer over the past several years and may reduce the chance of overtreatment.

The benefits of screening for prostate cancer may be realized years after treatment, while the harms may occur often and consistently throughout the rest of a man’s life. The harms resulting from screening may include:

  • False-positive results, which often lead to immediate, additional testing and years of additional close follow-up, including repeated blood tests and biopsies;
  • Overdiagnosis, which is the diagnosis of prostate cancer in some men who would not have experienced symptoms during their lifetime; and
  • Potential harms related to treatment, which commonly include erectile dysfunction and urinary incontinence.

The task force’s recommendation statement also contains specific sections that address men at increased risk — including African American men and patients with a family history — by providing more information for these men and their clinicians to consider as they make decisions about screening. Specifically, clinicians should inform their African American patients about their increased risk of developing and dying from prostate cancer, as well as the potential benefits and harms of screening. Clinicians should also speak to men with a family history of prostate cancer about their increased risk of developing the disease. This is particularly important for men whose father or brother was diagnosed at a younger age or died from prostate cancer.

The task force’s draft recommendation statement and draft evidence reviews were posted for public comment on the task force Web site from April 11, 2017, to May 8, 2017.

Read the full final recommendation statement here.

For more information: www.uspreventiveservicestaskforce.org

 

Related Content

Video Plus Brochure Helps Patients Make Lung Cancer Scan Decision

Image courtesy of the American Thoracic Society

News | Lung Cancer | April 19, 2019
A short video describing the potential benefits and risks of low-dose computed tomography (CT) screening for lung...
Artificial Intelligence Performs As Well As Experienced Radiologists in Detecting Prostate Cancer
News | Artificial Intelligence | April 18, 2019
University of California Los Angeles (UCLA) researchers have developed a new artificial intelligence (AI) system to...
Videos | Breast Imaging | April 18, 2019
In a keynote lecture at the Society of Breast Imaging (SBI)/American College of Radiology (ACR) 2019 Symposium, ...
Check-Cap Initiates U.S. Pilot Study of C-Scan for Colorectal Cancer Screening
News | Colonoscopy Systems | April 15, 2019
Check-Cap Ltd. has initiated its U.S. pilot study of the C-Scan system for prevention of colorectal cancer through...
Lunit Showcases AI Solution for Breast Cancer at SBI 2019
News | Artificial Intelligence | April 02, 2019
Medical artificial intelligence (AI) startup Lunit announced its attendance at the Society of Breast Imaging (SBI) 2019...
Researchers Use Radiomics to Predict Who Will Benefit from Chemotherapy
News | Radiomics | March 21, 2019
Using data from computed tomography (CT) images, researchers may be able to predict which lung cancer patients will...
Houston Methodist Hospital Acquires Focal One High-Intensity Focused Ultrasound System
News | Focused Ultrasound Therapy | March 19, 2019
EDAP TMS SA announced that Houston Methodist Hospital, one of the first hospitals in the U.S. to offer Ablatherm...
Older Biologic Age Linked to Elevated Breast Cancer Risk
News | Women's Health | March 19, 2019
Biologic age, a DNA-based estimate of a person’s age, is associated with future development of breast cancer, according...
Hologic Receives CE Mark for Three-in-One Omni Hysteroscope
News | Endoscopes | March 14, 2019
Hologic Inc. announced it has received a CE mark in Europe for its Omni hysteroscope, a three-in-one modular scope with...
Researchers Create New Method for Developing Cancer Imaging Isotopes

Prototype fluidic system for zirconium-89 purification. Image taken through a hot cell window at the Department of Radiology, University of Washington. Image courtesy of Matthew O’Hara, Pacific Northwest National Laboratory

News | Radiopharmaceuticals and Tracers | March 14, 2019
A team of researchers at the University of Washington announced they developed a new automated system for producing...